https://www.arubahealthmonitor.com/article/910555990-american-nurses-association-calls-for-nurse-led-guardrails-on-artificial-intelligence-in-healthcare Aruba Health Monitor en PressRelease 2026-05-05T16:46:15+00:00 American Nurses Association Calls for Nurse-Led Guardrails on Artificial Intelligence in Healthcare https://ml.globenewswire.com/media/ZmJhMWViYzAtNWRmOS00MDI4LThjMGEtNGFiODlhNzc2ZjZjLTUwMDE2MTk2Mi0yMDI2LTA1LTA1LWVu/tiny/American-Nurses-Enterprise.png https://www.arubahealthmonitor.com/article/910545481-valneva-to-report-first-quarter-2026-consolidated-financial-results-on-may-13-2026 Aruba Health Monitor en PressRelease 2026-05-05T15:45:00+00:00 Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026 https://ml-eu.globenewswire.com/media/04f398df-96ac-4b7a-8544-2a2ce2495778/small/val-logo-4c-jpg.jpg https://www.arubahealthmonitor.com/article/910545482-valneva-publiera-ses-r-sultats-financiers-consolid-s-du-premier-semestre-le-13-mai-2026 Aruba Health Monitor en PressRelease 2026-05-05T15:45:00+00:00 Valneva publiera ses résultats financiers consolidés du premier semestre le 13 mai 2026 https://ml-eu.globenewswire.com/media/04f398df-96ac-4b7a-8544-2a2ce2495778/small/ https://www.arubahealthmonitor.com/article/910545526-allsup-named-usa-today-s-top-workplace-third-year-in-a-row Aruba Health Monitor en PressRelease 2026-05-05T15:27:44+00:00 Allsup Named USA Today’s Top Workplace Third Year In A Row https://ml.globenewswire.com/media/OTVmNmRkNjctYjAzMC00Y2M3LTg2OTktODg4ZmQ5NjYxOTYxLTEwOTcwODEtMjAyNi0wNS0wNS1lbg==/tiny/Allsup.png https://www.arubahealthmonitor.com/article/910545507-correction-genembryomics-and-genomic-prediction-launch-xgen-pgt-x Aruba Health Monitor en PressRelease 2026-05-05T15:08:38+00:00 CORRECTION: GenEmbryomics and Genomic Prediction Launch XGEN PGT-X™ https://ml.globenewswire.com/media/ODM4NWIzMDItOGZhNy00ZTgyLWI5YTctNzE1NWI3MTk3MDU0LTEzMjMxNzktMjAyNi0wNS0wNS1lbg==/tiny/Genomic-Prediction.png https://www.arubahealthmonitor.com/article/910545505-wellspan-health-opens-carlisle-hospital-expanding-emergency-care-in-a-growing-cumberland-county-corridor Aruba Health Monitor en PressRelease 2026-05-05T15:07:16+00:00 WellSpan Health opens Carlisle hospital, expanding emergency care in a growing Cumberland County corridor https://ml.globenewswire.com/media/ZjI3MjljNTgtODgzMi00MGQ3LWJhMTQtZWFhNjVmMWZhZTRmLTEyMjE1MzQtMjAyNi0wNS0wNS1lbg==/tiny/WellSpan-Health.png https://www.arubahealthmonitor.com/article/910536173-canadian-soccer-standout-cloey-uddenberg-and-team-physician-dr-kevin-asem-join-lung-health-foundation-s-national-push-to-keep-kids-with-asthma-in-the Aruba Health Monitor en PressRelease 2026-05-05T15:00:00+00:00 Canadian Soccer Standout Cloey Uddenberg and Team Physician Dr. Kevin Asem Join Lung Health Foundation’s National Push to Keep Kids with Asthma in the Game https://ml.globenewswire.com/media/8463bfc8-e43b-49db-bf75-f2e28ae429c6/medium/play-prepared-ambassadors.jpg https://www.arubahealthmonitor.com/article/910536165-atos-and-cna-strengthen-long-term-strategic-partnership-through-new-multi-year-infrastructure-services-agreement Aruba Health Monitor en PressRelease 2026-05-05T14:49:42+00:00 Atos and CNA strengthen long-term strategic partnership through new multi-year infrastructure services agreement https://ml.globenewswire.com/media/3eacc37c-6163-4d11-95aa-944fca92da46/small/atos-logo-blue-rgb-png.png https://www.arubahealthmonitor.com/article/910536118-the-matcha-tokyo-brings-premium-japanese-matcha-culture-to-toronto-s-ossington-strip-with-first-canadian-location-opening-may-16 Aruba Health Monitor en PressRelease 2026-05-05T14:45:27+00:00 The Matcha Tokyo Brings Premium Japanese Matcha Culture to Toronto’s Ossington Strip with First Canadian Location Opening May 16 https://ml.globenewswire.com/media/Y2FiOWM5NDQtOTdkNy00ODEzLTlhN2UtZGEyZGUzMDMwZmI3LTUwMDE2MTk4NS0yMDI2LTA1LTA1LWVu/tiny/The-Matcha-Tokyo.png https://www.arubahealthmonitor.com/article/910535873-global-sleep-apnea-devices-market-projected-to-exceed-usd-11-61-billion-by-2032-marketsandmarkets Aruba Health Monitor en PressRelease 2026-05-05T14:45:00+00:00 Global Sleep Apnea Devices Market Projected to Exceed USD 11.61 Billion by 2032 | MarketsandMarkets™ https://ml.globenewswire.com/media/afcc5182-4ae0-43a8-a965-4351d590b7ed/small/mnm-logo-tm-jpg-jpg.JPG https://www.arubahealthmonitor.com/article/910536062-your-medicare-roadmap-what-to-know-before-you-turn-65 Aruba Health Monitor en PressRelease 2026-05-05T14:27:56+00:00 Your Medicare Roadmap: What to Know Before You Turn 65 https://ml.globenewswire.com/media/e29e0200-7282-4635-af4f-01abe250557e/small/feature-impact-editorlogin-logo2026-png.png https://www.arubahealthmonitor.com/article/910526322-new-aua-census-shows-shifts-in-urology-workforce-practice-workloads-and-ai-use Aruba Health Monitor en PressRelease 2026-05-05T14:02:00+00:00 New AUA Census Shows Shifts in Urology Workforce, Practice Workloads and AI Use https://ml.globenewswire.com/media/YWMwNjQ1Y2UtNjlmNy00MTUxLTkxMzQtYjBiNzFiNGJhNDQ5LTEyNzYxOTAtMjAyNi0wNS0wNS1lbg==/tiny/American-Urological-Associatio.png https://www.arubahealthmonitor.com/article/910526620-lighthouse-autism-center-opening-new-autism-therapy-center-in-council-bluffs-iowa Aruba Health Monitor en PressRelease 2026-05-05T14:00:29+00:00 Lighthouse Autism Center Opening New Autism Therapy Center in Council Bluffs, Iowa https://ml.globenewswire.com/media/e432b138-98bf-4971-921d-61bc5ac70fa7/small/lighthouse-primary-png.png https://www.arubahealthmonitor.com/article/910526308-bayridge-counselling-centres-and-no-fear-counselling-corp-merge-under-ch-y-qtel-wellness-to-form-canada-s-largest-first-nation-s-owned-mental-health Aruba Health Monitor en PressRelease 2026-05-05T14:00:00+00:00 Bayridge Counselling Centres and No Fear Counselling Corp Merge Under Ch’íyáqtel Wellness to Form Canada’s Largest First Nation’s Owned Mental Health Network https://ml.globenewswire.com/media/77b1c55c-807c-4a32-9598-7cafb1ac92c3/small/cw-new-logo-1-png.png https://www.arubahealthmonitor.com/article/910526359-aafa-leads-group-of-patients-clinicians-asking-congress-to-protect-programs-that-help-people-with-asthma-and-allergies Aruba Health Monitor en PressRelease 2026-05-05T14:00:00+00:00 AAFA Leads Group of Patients, Clinicians Asking Congress to Protect Programs that Help People with Asthma and Allergies https://ml.globenewswire.com/media/MDUxY2I5MTctZWI2Yy00NGExLThiMDEtNWM5ZjJkZDVhMWMzLTExMDE5NjItMjAyNi0wNS0wNS1lbg==/tiny/Asthma-and-Allergy-Foundation-.png https://www.arubahealthmonitor.com/article/910526516-lighthouse-autism-center-opening-new-autism-therapy-center-in-mount-pleasant-iowa Aruba Health Monitor en PressRelease 2026-05-05T13:48:22+00:00 Lighthouse Autism Center Opening New Autism Therapy Center in Mount Pleasant, Iowa https://ml.globenewswire.com/media/e432b138-98bf-4971-921d-61bc5ac70fa7/small/lighthouse-primary-png.png https://www.arubahealthmonitor.com/article/910526307-featol-introduces-back-brace-support-belt-for-everyday-lower-back-support Aruba Health Monitor en PressRelease 2026-05-05T13:32:00+00:00 FEATOL Introduces Back Brace Support Belt for Everyday Lower Back Support https://ml.globenewswire.com/media/b68de2c9-db44-424f-ba79-1b88cf5f3338/medium/featol-back-brace-rear-view-with-breathable-lightweight-mesh.png https://www.arubahealthmonitor.com/article/910517765-alpha-tau-announces-upcoming-podium-presentation-at-the-ahns-12th-international-conference-on-head-and-neck-cancer-showcasing-study-results-of-alpha Aruba Health Monitor en PressRelease 2026-05-05T13:14:32+00:00 Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910516832-sk-pharmteco-achieves-sbti-validation-for-2040-net-zero-science-based-targets Aruba Health Monitor en PressRelease 2026-05-05T13:03:00+00:00 SK pharmteco Achieves SBTi Validation for 2040 Net-Zero Science-Based Targets https://ml.globenewswire.com/media/038236c2-8cb0-4ff3-8b7e-cbb02b768b37/small/sk-pharmteco-3-png.png https://www.arubahealthmonitor.com/article/910516701-chemed-corporation-to-present-at-the-bank-of-america-securities-health-care-conference-2026 Aruba Health Monitor en PressRelease 2026-05-05T13:00:00+00:00 Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2026 https://ml.globenewswire.com/media/1ab951c0-8d76-40e0-bc65-ebeaa1731e66/small/chemed-corp-logo-600x400-jpg.jpg https://www.arubahealthmonitor.com/article/910516733-karl-jacob-s-fix-your-insulin-hits-1-amazon-best-seller-in-diabetes-category-launches-limited-time-0-99-reader-promotion Aruba Health Monitor en PressRelease 2026-05-05T13:00:00+00:00 Karl Jacob's "Fix Your Insulin" Hits #1 Amazon Best Seller in Diabetes Category, Launches Limited-Time $0.99 Reader Promotion https://pressranger.s3.us-west-1.amazonaws.com/3242430/The-Insulin-Fix_Cover-6.jpg https://www.arubahealthmonitor.com/article/910516841-heartsciences-signs-first-saas-revenues-agreement-following-full-launch-of-myovista-insights Aruba Health Monitor en PressRelease 2026-05-05T13:00:00+00:00 HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™ https://ml.globenewswire.com/media/800a6aae-74f3-42bb-9199-5e169ed9b881/small/heartsciences-png.png https://www.arubahealthmonitor.com/article/910517024-precision-optics-announces-receipt-of-3-5-million-follow-on-production-order-for-single-use-ophthalmic-program Aruba Health Monitor en PressRelease 2026-05-05T13:00:00+00:00 Precision Optics Announces Receipt of $3.5 Million Follow-On Production Order for Single-Use Ophthalmic Program https://ml.globenewswire.com/media/6d86ce33-7e41-41e5-90b0-1c74cd89785e/small/precision-optics-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910517058-bicycle-health-expands-leadership-team-to-increase-access-to-evidence-based-opioid-use-disorder-care Aruba Health Monitor en PressRelease 2026-05-05T13:00:00+00:00 Bicycle Health Expands Leadership Team to Increase Access to Evidence-Based Opioid Use Disorder Care https://ml.globenewswire.com/media/ba03cedc-3d11-4aa5-b226-cb5784309493/small/copy-of-bhvirtualcarelogo-black-2x-jpg.jpg https://www.arubahealthmonitor.com/article/910517073-maps-state-of-colorado-partner-to-deliver-free-harm-reduction-training-for-first-responders Aruba Health Monitor en PressRelease 2026-05-05T13:00:00+00:00 MAPS & State of Colorado Partner to Deliver Free Harm Reduction Training for First Responders https://ml.globenewswire.com/media/4f774750-4742-4818-be22-116e2b2085b1/small/maps-logo-2021-primary-horizontal-white-background-1200x486.jpg https://www.arubahealthmonitor.com/article/910517086-femasys-enables-ob-gyns-to-deliver-first-line-fertility-treatment-with-initial-commercial-use-of-femaseed-complete Aruba Health Monitor en PressRelease 2026-05-05T13:00:00+00:00 Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete https://ml.globenewswire.com/media/c668c3db-ff7f-4eb5-b51a-b8db25e838b4/small/femasys-logo-2-jpg.jpg https://www.arubahealthmonitor.com/article/910517333-health-canada-authorizes-north-america-s-first-hepatitis-b-rapid-test-biolytical-s-istatis-hepatitis-b-surface-antigen-test Aruba Health Monitor en PressRelease 2026-05-05T13:00:00+00:00 Health Canada Authorizes North America’s First Hepatitis B Rapid Test, bioLytical’s iStatis Hepatitis B Surface Antigen Test https://ml.globenewswire.com/media/8c4f4c4f-8565-4ee5-9842-ca4d0dcf67fb/medium/istatis-hepatitis-b-surface-antigen-test.jpg https://www.arubahealthmonitor.com/article/910517373-biosphere-awarded-9-million-u-s-army-contract-to-develop-on-demand-nutrition-production-system-for-warfighters Aruba Health Monitor en PressRelease 2026-05-05T13:00:00+00:00 Biosphere Awarded $9 Million U.S. Army Contract to Develop On-Demand Nutrition Production System for Warfighters https://ml.globenewswire.com/media/e816f42d-d6f4-462f-a3af-65eb8d733841/small/logo1-png.png https://www.arubahealthmonitor.com/article/910516816-cellution-biologics-celebrates-expansion-of-u-s-headquarters-in-roswell-georgia Aruba Health Monitor en PressRelease 2026-05-05T12:55:00+00:00 Cellution Biologics Celebrates Expansion of U.S. Headquarters in Roswell, Georgia https://ml.globenewswire.com/media/25f5b530-a1f5-4314-a4b9-9d2a0ec2a934/small/cb-logo-colorfs-png.png https://www.arubahealthmonitor.com/article/910517494-clearmind-medicine-announces-filing-of-european-patent-application-for-novel-psychedelic-compounds-for-the-treatment-of-ptsd Aruba Health Monitor en PressRelease 2026-05-05T12:50:00+00:00 Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD https://ml.globenewswire.com/media/bd17cbf4-8124-4f86-8a4c-1fafbb6785af/small/logo-jpg.jpg https://www.arubahealthmonitor.com/article/910517538-clene-announces-7-million-underwritten-offering-of-common-stock Aruba Health Monitor en PressRelease 2026-05-05T12:45:00+00:00 Clene Announces $7 Million Underwritten Offering of Common Stock https://ml.globenewswire.com/media/e9de96a4-582e-4975-8e43-6f3e6259c075/small/clene-logo-2x-png.png https://www.arubahealthmonitor.com/article/910507674-ocugen-provides-business-update-with-first-quarter-2026-financial-results Aruba Health Monitor en PressRelease 2026-05-05T12:32:54+00:00 Ocugen Provides Business Update with First Quarter 2026 Financial Results https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png https://www.arubahealthmonitor.com/article/910506917-sab-bio-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-may-12-2026-08-30-am-et Aruba Health Monitor en PressRelease 2026-05-05T12:30:00+00:00 SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET https://ml.globenewswire.com/media/6d99a771-f2c9-4d05-bf57-4f6c070df032/small/sabprimarylogocolorrgb900px72ppi-png.png https://www.arubahealthmonitor.com/article/910507058-ss-innovations-surpasses-10-500-surgeries-performed-with-the-ssi-mantra-surgical-robotic-system Aruba Health Monitor en PressRelease 2026-05-05T12:30:00+00:00 SS Innovations Surpasses 10,500 Surgeries Performed with the SSi Mantra Surgical Robotic System https://ml.globenewswire.com/media/cef267e0-040f-4889-a706-cc4d0ae49e55/small/new-logo-april-23-2025-png.png https://www.arubahealthmonitor.com/article/910507118-achieve-life-sciences-to-announce-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-12-2026 Aruba Health Monitor en PressRelease 2026-05-05T12:30:00+00:00 Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026 https://ml.globenewswire.com/media/1026e030-275c-4391-8f9a-65c5c1ec7b88/small/achieve-logo-717x800px-2-1-jpg.jpg https://www.arubahealthmonitor.com/article/910507145-sofwave-medical-reports-first-quarter-fiscal-2026-financial-results-and-business-highlights Aruba Health Monitor en PressRelease 2026-05-05T12:30:00+00:00 Sofwave Medical Reports First Quarter Fiscal 2026 Financial Results and Business Highlights https://ml.globenewswire.com/media/9fbd88c7-2eaf-45c3-b046-2d055fe94a07/small/download-png.png https://www.arubahealthmonitor.com/article/910507153-disc-medicine-reports-first-quarter-2026-financial-results-and-provides-business-update Aruba Health Monitor en PressRelease 2026-05-05T12:30:00+00:00 Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update https://ml.globenewswire.com/media/d212c899-9a87-4500-9382-573dfe9f12af/small/disc-logo-horiz-fullcolor-rgb-jpg.jpg https://www.arubahealthmonitor.com/article/910507252-palisade-bio-reports-additional-phase-1a-b-data-demonstrating-colon-targeted-exposure-and-sustained-ic90-coverage-supporting-once-daily-dosing-in Aruba Health Monitor en PressRelease 2026-05-05T12:30:00+00:00 Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis https://ml.globenewswire.com/media/0beaede8-1c7c-4f77-84a7-b1efd54c343c/small/logo-png.png https://www.arubahealthmonitor.com/article/910507258-cormedix-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-14-2026 Aruba Health Monitor en PressRelease 2026-05-05T12:30:00+00:00 CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026 https://ml.globenewswire.com/media/a14d732c-3f66-4a3c-96bb-7fc8ba5797bb/small/crmd-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910507278-fate-therapeutics-selected-for-u-s-fda-chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-to-support-manufacturing Aruba Health Monitor en PressRelease 2026-05-05T12:30:00+00:00 Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg https://www.arubahealthmonitor.com/article/910507452-oragenics-activates-second-site-in-phase-iia-clinical-trial-of-onp-002-for-concussion-and-mild-traumatic-brain-injury Aruba Health Monitor en PressRelease 2026-05-05T12:30:00+00:00 Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. https://ml.globenewswire.com/media/8b2c9d06-f009-4a6e-a465-8a1fe9640993/small/logo-jpg.jpg https://www.arubahealthmonitor.com/article/910507457-profusa-initiates-board-led-process-to-evaluate-strategic-alternatives-and-maximize-shareholder-value Aruba Health Monitor en PressRelease 2026-05-05T12:30:00+00:00 Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value https://ml.globenewswire.com/media/a8137a61-b858-48da-9e47-1f1bf8f6ddba/small/profusa-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910507458-imunon-to-hold-first-quarter-2026-financial-results-and-business-update-conference-call-on-tuesday-may-12-2026 Aruba Health Monitor en PressRelease 2026-05-05T12:30:00+00:00 IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026 https://ml.globenewswire.com/media/acf78e45-a45b-456b-93e3-0e39f2122826/small/logo-png.png https://www.arubahealthmonitor.com/article/910507620-microbot-medical-s-liberty-endovascular-robotic-system-is-now-adopted-by-multiple-accounts-across-key-territories-including-two-access-pvi-pivotal Aruba Health Monitor en PressRelease 2026-05-05T12:30:00+00:00 Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites https://ml.globenewswire.com/media/346df7fb-c134-40c2-970a-39bcbaf974cd/small/mbot-logo-rgb-jpg.jpg https://www.arubahealthmonitor.com/article/910507662-fibrobiologics-ceo-issues-letter-to-shareholders Aruba Health Monitor en PressRelease 2026-05-05T12:30:00+00:00 FibroBiologics CEO Issues Letter to Shareholders https://ml.globenewswire.com/media/f3ebedd0-66f2-4e20-b298-4b52bbb42404/medium/pete-o-heeron.jpg https://www.arubahealthmonitor.com/article/910507657-ocugen-inc-announces-pricing-of-115-million-of-6-75-convertible-senior-notes Aruba Health Monitor en PressRelease 2026-05-05T12:12:21+00:00 Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png https://www.arubahealthmonitor.com/article/910507636-blood-banking-devices-market-size-to-surpass-usd-9-08-bn-by-2034-driven-by-rising-number-of-blood-banks-globally Aruba Health Monitor en PressRelease 2026-05-05T12:06:12+00:00 Blood Banking Devices Market Size to Surpass USD 9.08 BN by 2034, Driven by Rising Number of Blood Banks Globally https://ml.globenewswire.com/media/1f4cf0ab-7d76-4136-a6dc-a5545f80f538/small/zion-market-research-jpg.jpg https://www.arubahealthmonitor.com/article/910507192-noom-names-power-of-habit-author-charles-duhigg-as-advisor-releases-new-research-linking-glp-1-success-to-habit-formation Aruba Health Monitor en PressRelease 2026-05-05T12:02:00+00:00 Noom Names “Power of Habit” Author Charles Duhigg as Advisor, Releases New Research Linking GLP-1 Success to Habit Formation https://ml.globenewswire.com/media/6b8c0d7a-2154-4867-82d3-f7e88a9793ee/medium/noom-psychosocial-report-findings.jpg https://www.arubahealthmonitor.com/article/910506877-allarity-therapeutics-advances-stenoparib-toward-pivotal-development-with-phase-3-manufacturing-campaign Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign https://ml-eu.globenewswire.com/media/fd1e4c64-f0cf-40e0-a0c9-0be0d6dce544/small/allarity-full-color-rgb-2023jun07-png.png https://www.arubahealthmonitor.com/article/910506884-spyre-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update https://ml.globenewswire.com/media/bc26a912-b583-43c6-8423-55a4ba2bf4bd/small/spyre-logo-horizontal-full-color-rgb-583px-300ppi-jpg.jpg https://www.arubahealthmonitor.com/article/910506912-nu-tek-biosciences-presents-data-driven-approach-to-animal-cell-culture-optimization-at-esact-2026 Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Nu-Tek BioSciences Presents Data-Driven Approach to Animal Cell Culture Optimization at ESACT 2026 https://ml.globenewswire.com/media/348e95f7-f41b-461f-94c6-c663f05170e8/small/nutek-logo-rgb-4x-jpg.jpg https://www.arubahealthmonitor.com/article/910506922-nu-tek-biosciences-pr-sentiert-auf-der-esact-2026-einen-datengest-tzten-ansatz-zur-optimierung-der-tierischen-zellkultur Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Nu-Tek BioSciences präsentiert auf der ESACT 2026 einen datengestützten Ansatz zur Optimierung der tierischen Zellkultur https://ml.globenewswire.com/media/348e95f7-f41b-461f-94c6-c663f05170e8/small/nutek-logo-rgb-4x-jpg.jpg https://www.arubahealthmonitor.com/article/910506928-nu-tek-biosciences-pr-sente-une-approche-fond-e-sur-les-donn-es-pour-l-optimisation-de-la-culture-de-cellules-animales-lors-de-l-esact-2026 Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Nu-Tek BioSciences présente une approche fondée sur les données pour l’optimisation de la culture de cellules animales lors de l’ESACT 2026 https://ml.globenewswire.com/media/348e95f7-f41b-461f-94c6-c663f05170e8/small/nutek-logo-rgb-4x-jpg.jpg https://www.arubahealthmonitor.com/article/910506939-healthverity-to-acquire-symphony-health-uniting-clinical-data-and-commercial-analytics-to-accelerate-breakthroughs-across-the-healthcare-ecosystem Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 HealthVerity to Acquire Symphony Health, Uniting Clinical Data and Commercial Analytics to Accelerate Breakthroughs Across the Healthcare Ecosystem https://ml.globenewswire.com/media/e2010eff-0993-44c1-a40d-9f0237268a35/medium/healthverity.jpg https://www.arubahealthmonitor.com/article/910506952-septerna-to-present-at-bank-of-america-securities-health-care-conference Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Septerna to Present at Bank of America Securities Health Care Conference https://ml.globenewswire.com/media/8c635733-2794-456f-9bc4-3b53908acba9/small/septernalogo-black-10x-jpg.jpg https://www.arubahealthmonitor.com/article/910507011-transplants-org-launches-as-centralized-education-and-navigation-platform-for-organ-and-stem-cell-transplant-patients Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Transplants.org Launches as Centralized Education and Navigation Platform for Organ and Stem Cell Transplant Patients https://ml.globenewswire.com/media/1d980326-1679-4adb-bd02-7e4358b841ce/small/transplants-org-logo-color-jpg.jpg https://www.arubahealthmonitor.com/article/910507047-clene-to-present-at-upcoming-may-conferences Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Clene to Present at Upcoming May Conferences https://ml.globenewswire.com/media/e9de96a4-582e-4975-8e43-6f3e6259c075/small/clene-logo-2x-png.png https://www.arubahealthmonitor.com/article/910507089-geron-plans-to-present-at-upcoming-investor-conferences Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Geron Plans to Present at Upcoming Investor Conferences https://ml.globenewswire.com/media/e184bb51-5636-436e-8964-15613f24ca1f/small/geron-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910507095-minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates https://ml.globenewswire.com/media/69e604cb-25b6-4235-ae9a-17c25cc158b9/small/minerva-logo.jpg https://www.arubahealthmonitor.com/article/910507163-cg-oncology-to-present-at-upcoming-investor-conferences-in-may Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 CG Oncology to Present at Upcoming Investor Conferences in May https://ml.globenewswire.com/media/9e1cbdea-928e-4ea4-b4cd-33cdc36c6b2f/small/cgoncology-cover-jpg.jpg https://www.arubahealthmonitor.com/article/910507196-corbus-pharmaceuticals-to-host-in-person-and-virtual-kol-event-at-asco-2026 Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 https://ml.globenewswire.com/media/459d6fb1-b336-4d47-8aa1-f9198bda891d/small/corbus-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910507205-zentalis-pharmaceuticals-announces-first-patient-dosed-in-aspenova-phase-3-trial-of-azenosertib-in-patients-with-cyclin-e1-positive-platinum-resistant Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer https://ml.globenewswire.com/media/1b481d6d-51c9-44f0-b33f-81feb1061d2e/small/zentalis-logo-png.png https://www.arubahealthmonitor.com/article/910507214-picard-medical-announces-pricing-of-5-million-offering Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Picard Medical Announces Pricing of $5 Million Offering https://ml.globenewswire.com/media/93c733bb-b54a-41af-856b-6d01c1f724a2/small/syncardia-x-picard-email-signature-2025-1-png.png https://www.arubahealthmonitor.com/article/910507244-filana-therapeutics-presents-tsc-related-epilepsy-program-at-eilat-xviii Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII https://ml.globenewswire.com/media/984a6554-2b2a-4cf7-9a32-72ac808d52ac/small/filana400-png.png https://www.arubahealthmonitor.com/article/910507247-madrigal-adds-clinical-stage-sirna-asset-targeting-pnpla3-to-its-mash-pipeline Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline https://ml.globenewswire.com/media/8fec8de1-1a2e-4f6c-a679-fc43002276ba/small/madrigal-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910507268-pathai-and-a-c-camargo-cancer-center-announce-cooperation-to-expand-digital-pathology-with-ai-in-brazil-via-sus Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 PathAI and A.C.Camargo Cancer Center Announce Cooperation to Expand Digital Pathology with AI in Brazil via SUS https://ml.globenewswire.com/media/ab2bfc12-ae80-47c6-9345-a98783489ed7/small/pathai-logo-standard-png.png https://www.arubahealthmonitor.com/article/910507406-cogent-biosciences-reports-recent-business-highlights-and-first-quarter-2026-financial-results Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results https://ml.globenewswire.com/media/2b8cbfab-a4de-4e17-bdd6-7ef597a95d2e/small/cogent-biosciences-logo-rgb-png.png https://www.arubahealthmonitor.com/article/910507408-verrica-pharmaceuticals-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-12-2026 Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026 https://ml.globenewswire.com/media/4938c2eb-43f1-4f6c-a1e1-82ab7fb66c3b/small/verrica-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910507428-bionano-announces-a-56-increase-in-publications-describing-the-utility-of-ogm-in-rare-diseases-in-q1-2026-vs-q1-2025 Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025 https://ml.globenewswire.com/media/5ba4072e-6e59-46e7-847c-6aaf7755bbbf/small/bionano-rgb-png.png https://www.arubahealthmonitor.com/article/910507624-mineralys-therapeutics-to-participate-in-the-bank-of-america-securities-health-care-conference Aruba Health Monitor en PressRelease 2026-05-05T12:00:00+00:00 Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference https://ml.globenewswire.com/media/2f3e6873-8e64-406e-832e-7df0f6d79a56/small/mineralys-therapeutics-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910507632-latest-digestive-health-supplements-market-size-expected-to-reach-usd-25-86-billion-by-2034-with-6-10-cagr-driven-by-rising-geriatric-population Aruba Health Monitor en PressRelease 2026-05-05T11:59:13+00:00 [Latest] Digestive Health Supplements Market Size Expected to Reach USD 25.86 Billion by 2034 With 6.10% CAGR, Driven by Rising Geriatric Population Worldwide and Increasing Prevalence of Digestive Health Concerns https://ml.globenewswire.com/media/1f4cf0ab-7d76-4136-a6dc-a5545f80f538/small/zion-market-research-jpg.jpg https://www.arubahealthmonitor.com/article/910507208-neuronetics-reports-first-quarter-2026-financial-and-operating-results Aruba Health Monitor en PressRelease 2026-05-05T11:50:00+00:00 Neuronetics Reports First Quarter 2026 Financial and Operating Results https://ml.globenewswire.com/media/12db9039-d4bf-41a0-8b4a-324398e392b4/small/neuronetics-logo-rgb-purple-png.png https://www.arubahealthmonitor.com/article/910497076-discure-technologies-appoints-dr-ray-baker-to-its-board-of-directors Aruba Health Monitor en PressRelease 2026-05-05T11:35:00+00:00 Discure Technologies Appoints Dr. Ray Baker to its Board of Directors https://ml.globenewswire.com/media/eb02cf21-747a-4619-8cb2-b3929c46ae7e/small/descure-technologies-logo-png.PNG https://www.arubahealthmonitor.com/article/910497087-kura-oncology-to-report-first-quarter-2026-financial-results Aruba Health Monitor en PressRelease 2026-05-05T11:30:00+00:00 Kura Oncology to Report First Quarter 2026 Financial Results https://ml.globenewswire.com/media/ebf510d7-3727-4cc8-894f-6ce2d82b941a/small/kura-logo-for-globe-newswire-prs-png.png https://www.arubahealthmonitor.com/article/910497096-intellia-therapeutics-to-participate-in-upcoming-investor-conferences Aruba Health Monitor en PressRelease 2026-05-05T11:30:00+00:00 Intellia Therapeutics to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a/small/intellia-jpg.jpg https://www.arubahealthmonitor.com/article/910497121-compass-therapeutics-reports-2026-first-quarter-financial-results-and-provides-corporate-update Aruba Health Monitor en PressRelease 2026-05-05T11:30:00+00:00 Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update  https://ml.globenewswire.com/media/b8470129-5d30-4368-8074-d77404b65be8/small/compass-logo-rgb-outlines-png.png https://www.arubahealthmonitor.com/article/910497160-bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece Aruba Health Monitor en PressRelease 2026-05-05T11:30:00+00:00 BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE https://ml.globenewswire.com/media/2074ba9b-0e5b-41fa-baac-553f1345bb75/small/bridge-bio-black-png.png https://www.arubahealthmonitor.com/article/910497222-surgery-partners-inc-announces-first-quarter-2026-results-reaffirms-full-year-2026-guidance Aruba Health Monitor en PressRelease 2026-05-05T11:30:00+00:00 Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance https://ml.globenewswire.com/media/d0188456-e6d3-48f9-8479-b40422f00e4c/small/surgerypartnerslinear-1-jpg.jpg https://www.arubahealthmonitor.com/article/910497278-tris-pharma-appoints-jim-potenziano-ph-d-as-chief-science-and-development-officer Aruba Health Monitor en PressRelease 2026-05-05T11:30:00+00:00 Tris Pharma Appoints Jim Potenziano, Ph.D. as Chief Science and Development Officer https://ml.globenewswire.com/media/2ab6667c-5742-4090-afb8-459cd811c92e/small/logo-png.png https://www.arubahealthmonitor.com/article/910497407-cytokinetics-announces-positive-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive Aruba Health Monitor en PressRelease 2026-05-05T11:30:00+00:00 Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy https://ml.globenewswire.com/media/adcf634e-a2a7-4cdf-98b3-ca658eab1b35/medium/figure-1-assessments-of-kccq-and-pvo2.png https://www.arubahealthmonitor.com/article/910497479-nuvectis-pharma-inc-reports-first-quarter-2026-financial-results-and-business-highlights Aruba Health Monitor en PressRelease 2026-05-05T11:30:00+00:00 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights https://ml.globenewswire.com/media/aceda01c-bc94-4579-88fa-c0294406b49f/small/nuvectispharma-logos-final-full-color-png.png https://www.arubahealthmonitor.com/article/910497039-what-to-look-for-in-a-deodorant-in-canada-in-2026 Aruba Health Monitor en PressRelease 2026-05-05T11:12:15+00:00 What to Look for in a Deodorant in Canada in 2026 https://ml-eu.globenewswire.com/media/MmU2ZTI3ZDAtOWNkMi00Y2Y4LWE5N2EtZWFiZTg0NGFjZTk0LTEzMjI4ODctMjAyNi0wNS0wNS1lbg==/tiny/Beiersdorf-Canada-Inc-.png https://www.arubahealthmonitor.com/article/910497392-cellectar-biosciences-reports-positive-12-month-follow-up-data-from-phase-2b-clover-wam-study-demonstrating-durable-responses-and-efficacy-of Aruba Health Monitor en PressRelease 2026-05-05T11:10:00+00:00 Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia https://ml.globenewswire.com/media/980abc5d-826f-4ac3-ad81-f07d69b34af6/small/cellectar-logo-1-jpg.jpg https://www.arubahealthmonitor.com/article/910497403-uniqure-announces-first-quarter-2026-financial-results-and-provides-recent-company-updates Aruba Health Monitor en PressRelease 2026-05-05T11:05:00+00:00 uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates https://ml.globenewswire.com/media/2ba61fe2-12e5-4a01-afe1-419652b31512/small/logo-uniqure-ms-word-orange-jpg.jpg https://www.arubahealthmonitor.com/article/910497470-sotera-health-delivers-strong-first-quarter-2026-results-and-reaffirms-2026-outlook Aruba Health Monitor en PressRelease 2026-05-05T11:03:49+00:00 Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook https://ml.globenewswire.com/media/a0ec722c-ad65-4f05-a8ae-bc1aa6cc4db4/small/sotera-png.png https://www.arubahealthmonitor.com/article/910497148-invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Aruba Health Monitor en PressRelease 2026-05-05T11:01:00+00:00 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/7bf12f50-1073-4ce7-81ac-89426c07add3/small/untitled-design-2-png.png https://www.arubahealthmonitor.com/article/910497078-biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/8b033909-1a3c-4811-b07b-fe03b12e00d2/small/biocryst-primarylogo-r-2c-rgb-jpg.jpg https://www.arubahealthmonitor.com/article/910497083-dupixent-dupilumab-demonstrates-improved-esophageal-function-in-eosinophilic-esophagitis-eoe-phase-4-trial Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910497093-kymera-therapeutics-presents-new-preclinical-ibd-data-for-kt-579-a-first-in-class-oral-irf5-degrader-at-digestive-disease-week Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week https://ml.globenewswire.com/media/4d3d3283-c57d-401e-9e1b-53f17e22d76b/small/kymera-logo-rgb-denim-marigold-high-res-png.png https://www.arubahealthmonitor.com/article/910497116-orvida-pharma-to-present-functional-endpoint-development-data-in-rare-palmoplantar-skin-disorders-at-the-83rd-annual-meeting-of-the-society-for Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Orvida Pharma to Present Functional Endpoint Development Data in Rare Palmoplantar Skin Disorders at the 83rd Annual Meeting of the Society for Investigative Dermatology and the 2026 Epidermal Differentiation Disorders Symposium https://ml.globenewswire.com/media/cd4d7fc1-6bca-4b1d-a6b3-2314ed21fb79/small/orvida-final-46-jpg.jpg https://www.arubahealthmonitor.com/article/910497194-editas-medicine-announces-first-quarter-2026-results-and-business-updates Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Editas Medicine Announces First Quarter 2026 Results and Business Updates https://ml.globenewswire.com/media/03686b66-5cbc-40b5-9dfa-be0e7858ac97/small/editas-logo-small-1-jpg.jpg https://www.arubahealthmonitor.com/article/910497200-climb-bio-hosts-budoprutug-r-d-spotlight-event-highlighting-topline-subcutaneous-formulation-data-broad-b-cell-mediated-disease-opportunity-and Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts https://ml.globenewswire.com/media/2a42b557-6e44-4818-bfce-2238a05f2c43/small/climb-400x400-002-jpg.jpg https://www.arubahealthmonitor.com/article/910497206-arvinas-to-report-first-quarter-2026-financial-results-on-may-12-2026 Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 https://ml.globenewswire.com/media/563780a0-f8d9-4e37-8665-b622ef2caa5b/small/arvinas-logoart-lg-jpg.jpg https://www.arubahealthmonitor.com/article/910497213-sotera-health-announces-leadership-transition Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Sotera Health Announces Leadership Transition https://ml.globenewswire.com/media/a0ec722c-ad65-4f05-a8ae-bc1aa6cc4db4/small/sotera-png.png https://www.arubahealthmonitor.com/article/910497215-relmada-therapeutics-to-present-ndv-01-abstracts-at-aua2026 Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 https://ml.globenewswire.com/media/8a986b0a-11c8-4551-b0ad-ec20fe2fe40a/small/relmada-logo-png.png https://www.arubahealthmonitor.com/article/910497218-fractyl-health-to-report-first-quarter-2026-financial-results-and-provide-business-updates-on-may-12-2026-and-will-participate-in-an-upcoming Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference https://ml.globenewswire.com/media/3a379315-9c07-4655-883e-7e7f26c67778/small/fractyl-logo-png.png https://www.arubahealthmonitor.com/article/910497220-electra-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-ipsoprubart-ela026-in-t-cell-malignancies Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies https://ml.globenewswire.com/media/5c28c3ad-0aec-4979-b6c4-12f1d4bf4c46/small/electra-logo-rgb-png.png https://www.arubahealthmonitor.com/article/910497226-brewdog-announces-partnership-with-underbelly-as-official-beer-supplier-of-underbelly-at-the-edinburgh-fringe Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 BrewDog Announces Partnership with Underbelly as Official Beer Supplier of Underbelly at the Edinburgh Fringe https://ml.globenewswire.com/media/dc1f57dc-8a83-444e-8722-08f858c451af/medium/brewdog-underbelly.jpeg https://www.arubahealthmonitor.com/article/910497233-axsome-therapeutics-to-participate-in-upcoming-investor-conferences Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Axsome Therapeutics to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/1186f248-bfb6-4258-a391-f2ffd94c5d76/small/axsome-r-morpheus-logo-pos-rgb-png.png https://www.arubahealthmonitor.com/article/910497236-repligen-reports-first-quarter-2026-financial-results-and-updates-full-year-2026-financial-guidance Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance https://ml.globenewswire.com/media/967d43f6-7ffd-4ee0-8804-e3c12952402f/small/repligen-logo-horizontal-withtagline-1-jpg.jpg https://www.arubahealthmonitor.com/article/910497247-atea-pharmaceuticals-to-host-first-quarter-2026-financial-results-and-business-update-conference-call-on-may-12-2026 Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026 https://ml.globenewswire.com/media/1506ab30-7618-4ed0-98de-e3815adb3aa6/small/avir-png.png https://www.arubahealthmonitor.com/article/910497290-seres-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates https://ml.globenewswire.com/media/f8c3ad50-d1a3-457d-b0c7-8f9237db7f93/small/seres-logo-png.png https://www.arubahealthmonitor.com/article/910497311-eupraxia-pharmaceuticals-reports-erefs-data-from-its-ongoing-phase-1b-2a-resolve-trial-in-eosinophilic-esophagitis-at-digestive-disease-week-ddw Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) https://ml.globenewswire.com/media/0b2bbe4b-1cf9-402e-8ea6-22c0043f310a/small/eupraxia-color-med-res-01-jpg.jpg https://www.arubahealthmonitor.com/article/910497313-ocular-therapeutix-reports-first-quarter-2026-financial-results-and-business-highlights Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910497336-rhythm-pharmaceuticals-reports-first-quarter-2026-financial-results-and-business-update Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update https://ml.globenewswire.com/media/b767aaa5-9915-465f-9233-d97757f4e387/small/rhythm-logo-rgb-jpg-registration-mark-jpg.jpg https://www.arubahealthmonitor.com/article/910497362-nrx-pharmaceuticals-nasdaq-nrxp-announces-initiation-of-commercial-manufacturing-for-preservative-free-ketamine Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png https://www.arubahealthmonitor.com/article/910497386-neuraxis-to-host-first-quarter-2026-results-and-business-update-call-on-tuesday-may-12-2026 Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026 https://ml.globenewswire.com/media/a1e3887d-3378-46c5-938d-2b0d5a7c825f/small/neuraxis-logo-png.png https://www.arubahealthmonitor.com/article/910497398-shopify-delivers-again-as-merchants-clear-100-billion-in-q1-gmv Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Shopify Delivers Again as Merchants Clear $100 Billion in Q1 GMV https://ml.globenewswire.com/media/28cdf29b-fa48-43e3-a710-ea3ab811a26c/small/shopify-logo-black-png.png https://www.arubahealthmonitor.com/article/910497412-cellectar-biosciences-announces-oversubscribed-financing-up-to-140-million Aruba Health Monitor en PressRelease 2026-05-05T11:00:00+00:00 Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million https://ml.globenewswire.com/media/980abc5d-826f-4ac3-ad81-f07d69b34af6/small/cellectar-logo-1-jpg.jpg https://www.arubahealthmonitor.com/article/910487809-biontech-ver-ffentlicht-ergebnisse-f-r-das-erste-quartal-2026-sowie-informationen-zur-gesch-ftsentwicklung Aruba Health Monitor en PressRelease 2026-05-05T10:45:00+00:00 BioNTech veröffentlicht Ergebnisse für das erste Quartal 2026 sowie Informationen zur Geschäftsentwicklung https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/ https://www.arubahealthmonitor.com/article/910487854-biontech-announces-first-quarter-2026-financial-results-and-corporate-update Aruba Health Monitor en PressRelease 2026-05-05T10:45:00+00:00 BioNTech Announces First Quarter 2026 Financial Results and Corporate Update https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/190705-biontech-logo-rgb-dark-green-preferred-0-png.png https://www.arubahealthmonitor.com/article/910488042-diagonal-therapeutics-expands-executive-leadership-team-appoints-industry-veteran-jonathan-piazza-as-chief-financial-officer Aruba Health Monitor en PressRelease 2026-05-05T10:30:00+00:00 Diagonal Therapeutics Expands Executive Leadership Team, Appoints Industry Veteran Jonathan Piazza as Chief Financial Officer https://ml.globenewswire.com/media/c2298dfb-0954-43a2-ae2e-866e7a08c7ad/small/diagonallogo-darkcolor-png.png https://www.arubahealthmonitor.com/article/910487933-new-cda-data-reveals-disconnect-between-knowing-the-risks-of-tanning-and-behaviour-among-gen-z Aruba Health Monitor en PressRelease 2026-05-05T10:00:00+00:00 New CDA Data Reveals Disconnect Between Knowing the Risks of Tanning and Behaviour Among Gen Z https://ml.globenewswire.com/media/b78c656b-c304-4227-95af-3944fa238da2/medium/sun-awareness-month-2026.png https://www.arubahealthmonitor.com/article/910487988-de-nouvelles-donn-es-de-l-acd-r-v-lent-un-d-calage-entre-la-conscience-de-la-g-n-ration-z-des-risques-li-s-au-bronzage-et-ses-habitudes-de-protection Aruba Health Monitor en PressRelease 2026-05-05T10:00:00+00:00 De nouvelles données de l’ACD révèlent un décalage entre la conscience de la génération Z des risques liés au bronzage et ses habitudes de protection solaire https://ml.globenewswire.com/media/b78c656b-c304-4227-95af-3944fa238da2/medium/mois-de-mai-le-mois-de-la-prudence-au-soleil-2026.png https://www.arubahealthmonitor.com/article/910488059-paws-itively-paw-litical-voting-opens-for-4th-annual-cutest-pets-on-parliament-hill Aruba Health Monitor en PressRelease 2026-05-05T10:00:00+00:00 Paws-itively Paw-litical: Voting Opens for 4th Annual Cutest Pets on Parliament Hill https://ml.globenewswire.com/media/197c2953-84e0-435d-8524-c68da19d27e9/small/cahi-logo-jpg.JPG https://www.arubahealthmonitor.com/article/910488062-poil-itiquement-patte-tant-le-vote-est-ouvert-pour-le-quatri-me-concours-annuel-les-animaux-de-compagnie-les-plus-mignons-sur-la-colline-du Aruba Health Monitor en PressRelease 2026-05-05T10:00:00+00:00 Poil-itiquement é-patte-tant : Le vote est ouvert pour le quatrième concours annuel « Les animaux de compagnie les plus mignons sur la Colline du Parlement » https://ml.globenewswire.com/media/197c2953-84e0-435d-8524-c68da19d27e9/small/cahi-logo-jpg.JPG https://www.arubahealthmonitor.com/article/910488114-integra-lifesciences-announces-leadership-transition Aruba Health Monitor en PressRelease 2026-05-05T10:00:00+00:00 Integra LifeSciences Announces Leadership Transition https://ml.globenewswire.com/media/5adce648-cb01-457f-83ba-c7a1895d1515/medium/stuart-essig-chairman-and-chief-executive-officer.png https://www.arubahealthmonitor.com/article/910488123-fortrea-reports-first-quarter-2026-results Aruba Health Monitor en PressRelease 2026-05-05T10:00:00+00:00 Fortrea Reports First Quarter 2026 Results https://ml.globenewswire.com/media/9fbbe00b-8782-464e-83e6-5843c563884a/small/fortrea-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910488127-aclarion-announces-second-commercial-agreement-with-weill-cornell-medicine Aruba Health Monitor en PressRelease 2026-05-05T10:00:00+00:00 Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine https://ml.globenewswire.com/media/6650177f-80b7-4c94-afb4-fc63aa3ada98/small/logo-png.png https://www.arubahealthmonitor.com/article/910488131-integra-lifesciences-reports-first-quarter-2026-financial-results Aruba Health Monitor en PressRelease 2026-05-05T10:00:00+00:00 Integra LifeSciences Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/80d27f1a-2d8e-44f2-92e9-57e14db38652/small/integra-promotional-logos-integra-logo-full-color-process-1.png https://www.arubahealthmonitor.com/article/910488144-anteris-technologies-announces-first-u-s-patients-treated-in-global-pivotal-paradigm-trial Aruba Health Monitor en PressRelease 2026-05-05T10:00:00+00:00 Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial https://ml.globenewswire.com/media/90a5ae8d-7cf0-4a3d-b38c-f4ad7e3fbf0e/small/anteris-tech-rgb-blue-png.png https://www.arubahealthmonitor.com/article/910458835-latest-findings-from-dme-aware-delphi-study-presented-at-arvo-2026-annual-meeting Aruba Health Monitor en PressRelease 2026-05-05T08:00:00+00:00 Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting https://ml-eu.globenewswire.com/media/dc25de9c-07c8-448a-b6af-aea02249e593/medium/global-consensus-on-early-intervention-in-dme.png https://www.arubahealthmonitor.com/article/910448820-4bio-capital-leads-oversubscribed-61-million-83m-series-a-financing-of-cytospire-therapeutics Aruba Health Monitor en PressRelease 2026-05-05T07:05:00+00:00 4BIO Capital leads oversubscribed £61 million ($83m) Series A financing of Cytospire Therapeutics  https://ml-eu.globenewswire.com/media/fab6412c-5edc-4903-8a71-51e5ccc6accb/small/4bio-capital-logo-png.png https://www.arubahealthmonitor.com/article/910448817-cytospire-therapeutics-announces-oversubscribed-61-million-83m-series-a-financing-to-advance-pipeline-of-first-in-class-pan-gamma-delta-t-cell Aruba Health Monitor en PressRelease 2026-05-05T07:00:00+00:00 Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer https://ml-eu.globenewswire.com/media/99e8d7e3-84e7-41a5-84aa-4f03dcb8e2be/medium/natalie-mount.jpg https://www.arubahealthmonitor.com/article/910448827-neurocare-ag-mdma-tms Aruba Health Monitor en PressRelease 2026-05-05T07:00:00+00:00 تعلن مجموعة neurocare AG عن ترخيص تسويق الأجهزة الطبية (MDMA) لبيع أجهزة التحفيز المغناطيسي عبر الجمجمة (TMS) في المملكة العربية السعودية https://ml-eu.globenewswire.com/media/d4455b17-37a7-4b42-8dc5-719bbbfe483b/medium/patient-receives-tms-therapy-for-depression-with-neurocare-s.jpg https://www.arubahealthmonitor.com/article/910448841-neurocare-group-ag-announces-mdma-approval-of-tms-devices-in-saudi-arabia Aruba Health Monitor en PressRelease 2026-05-05T07:00:00+00:00 neurocare group AG announces MDMA approval of TMS Devices in Saudi Arabia https://ml-eu.globenewswire.com/media/d4455b17-37a7-4b42-8dc5-719bbbfe483b/medium/patient-receives-depression-treatment-using-neurocares-apoll.jpg https://www.arubahealthmonitor.com/article/910448845-novonesis-delivered-strong-start-to-the-year-with-7-organic-sales-growth-in-q1 Aruba Health Monitor en PressRelease 2026-05-05T06:18:16+00:00 Novonesis delivered strong start to the year with 7% organic sales growth in Q1 https://ml-eu.globenewswire.com/media/d0c3bcb0-65ab-400f-9219-15fbf4253148/small/novonesis-logo-1-png.png https://www.arubahealthmonitor.com/article/910439198-abivax-announces-repurchase-of-royalty-certificates-and-pricing-of-45m-38-5m-offering-of-american-depositary-shares Aruba Health Monitor en PressRelease 2026-05-05T06:00:00+00:00 Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/abivax-logo-rgb-png.png https://www.arubahealthmonitor.com/article/910429701-santhera-ver-ffentlicht-einladung-zur-ordentlichen-generalversammlung Aruba Health Monitor en PressRelease 2026-05-05T05:00:00+00:00 Santhera veröffentlicht Einladung zur ordentlichen Generalversammlung https://ml-eu.globenewswire.com/media/63cd960e-70ce-4ba8-8984-92f72954c235/small/ https://www.arubahealthmonitor.com/article/910429709-santhera-publishes-agenda-for-its-annual-general-meeting Aruba Health Monitor en PressRelease 2026-05-05T05:00:00+00:00 Santhera Publishes Agenda for its Annual General Meeting https://ml-eu.globenewswire.com/media/63cd960e-70ce-4ba8-8984-92f72954c235/small/logo-jpg.JPG https://www.arubahealthmonitor.com/article/910410639-axavive-under-investigation-inspecting-the-axon-renewal-anti-aging-benefits-of-the-secret-golden-seed-astragaloside-iv-skin-care-supplement Aruba Health Monitor en PressRelease 2026-05-05T02:59:01+00:00 Axavive Under Investigation: Inspecting the Axon Renewal Anti-Aging Benefits of the Secret Golden Seed Astragaloside IV Skin Care Supplement https://zingfast.com/wp-content/uploads/2026/05/Axavive-Axon-Renewal.jpg https://www.arubahealthmonitor.com/article/910400806-gl-control-claims-evaluated-investigating-the-ingredients-benefits-for-blood-sugar-trap-support Aruba Health Monitor en PressRelease 2026-05-05T02:26:09+00:00 GL Control Claims Evaluated: Investigating the Ingredients Benefits for Blood Sugar Trap Support https://zingfast.com/wp-content/uploads/2026/05/GL-Control-1.jpg https://www.arubahealthmonitor.com/article/910400749-vital-wrist-monitor-vital-wrist-ball-under-investigation-evaluating-the-brand-claims-product-benefits Aruba Health Monitor en PressRelease 2026-05-05T01:55:19+00:00 Vital Wrist Monitor & Vital Wrist Ball Under Investigation: Evaluating the Brand Claims & Product Benefits https://zingfast.com/wp-content/uploads/2026/05/Vital-Wrist-Monitor-Vital-Wrist-Ball.jpg https://www.arubahealthmonitor.com/article/910391392-apa-welcomes-national-focus-on-mental-health-urges-evidence-based-approach-and-continued-focus-on-access-to-care Aruba Health Monitor en PressRelease 2026-05-05T01:41:48+00:00 APA Welcomes National Focus on Mental Health, Urges Evidence-Based Approach and Continued Focus on Access to Care https://ml.globenewswire.com/media/ODc3ZjcyMWMtNDEyOC00Njc4LWE1MzQtNjQ0YzkzNjhiZDI4LTEyNjc0MTAtMjAyNi0wNS0wNS1lbg==/tiny/American-Psychiatric-Associati.png https://www.arubahealthmonitor.com/article/910391357-axavive-claims-evaluated-the-golden-seed-switch-for-healthy-skin-support Aruba Health Monitor en PressRelease 2026-05-05T01:28:26+00:00 Axavive Claims Evaluated: The Golden Seed Switch for Healthy Skin Support https://zingfast.com/wp-content/uploads/2026/05/Axavive.jpg https://www.arubahealthmonitor.com/article/910371205-pennant-announces-first-quarter-2026-earnings-release-and-call Aruba Health Monitor en PressRelease 2026-05-04T23:34:37+00:00 Pennant Announces First Quarter 2026 Earnings Release and Call https://ml.globenewswire.com/media/d50f543c-fc54-437d-8007-600644587dfe/small/pennant-logo-png.png https://www.arubahealthmonitor.com/article/910361255-janell-rae-releases-debut-book-satori-awakening-to-your-truest-self-through-energy-intelligence Aruba Health Monitor en PressRelease 2026-05-04T22:40:00+00:00 Janell Rae Releases Debut Book Satori: Awakening to Your Truest Self Through Energy Intelligence https://pressranger.s3.us-west-1.amazonaws.com/3225770/Janell-Book-Cover-%288%29.png https://www.arubahealthmonitor.com/article/910351918-ballad-health-invests-15-million-to-expand-robotic-assisted-surgery-earns-national-accreditation-for-quality-and-surgical-excellence Aruba Health Monitor en PressRelease 2026-05-04T22:28:36+00:00 Ballad Health invests $15 million to expand robotic-assisted surgery, earns national accreditation for quality and surgical excellence https://ml.globenewswire.com/media/ODk2ZWQ5ZTQtY2ZhZC00YzBmLTkyNDQtNTg2Y2VhYzgxZTkyLTExMzUxNTItMjAyNi0wNS0wNC1lbg==/tiny/Ballad-Health.png https://www.arubahealthmonitor.com/article/910351879-elite-pro-force-male-enhancement-gummies-claims-evaluated-the-ultra-peak-horse-gelatin-trick-for-men Aruba Health Monitor en PressRelease 2026-05-04T21:49:17+00:00 Elite Pro Force Male Enhancement Gummies Claims Evaluated: The Ultra Peak Horse Gelatin Trick for Men https://zingfast.com/wp-content/uploads/2026/05/Elite-Pro-Force-Male-Enhancement-Gummies.jpg https://www.arubahealthmonitor.com/article/910342560-nanobiotix-announces-protocol-amendment-to-ongoing-global-phase-3-head-and-neck-cancer-study Aruba Health Monitor en PressRelease 2026-05-04T21:29:27+00:00 Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910342587-nanobiotix-annonce-un-amendement-du-protocole-de-l-tude-mondiale-de-phase-3-sur-le-cancer-de-la-t-te-et-du-cou Aruba Health Monitor en PressRelease 2026-05-04T21:29:27+00:00 NANOBIOTIX ANNONCE UN AMENDEMENT DU PROTOCOLE DE L’ÉTUDE MONDIALE DE PHASE 3 SUR LE CANCER DE LA TÊTE ET DU COU https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910342441-jellyfit-claims-evaluated-the-truth-about-jelly-lean-fit-weight-loss-drops-8-ingredients-stacked-with-gelatin-trick-recipe-hack-exposed Aruba Health Monitor en PressRelease 2026-05-04T21:07:11+00:00 JellyFit Claims Evaluated: The Truth About Jelly Lean Fit Weight Loss Drops' 8 Ingredients Stacked with Gelatin Trick Recipe Hack Exposed https://zingfast.com/wp-content/uploads/2026/05/Jelly-Lean-Fit-Weight-Loss-Drops.jpg https://www.arubahealthmonitor.com/article/910342340-dentsply-sirona-expands-u-s-distribution-footprint-through-enhanced-agreement-with-atlanta-dental-supply Aruba Health Monitor en PressRelease 2026-05-04T21:00:00+00:00 Dentsply Sirona Expands U.S. Distribution Footprint Through Enhanced Agreement with Atlanta Dental Supply https://ml.globenewswire.com/media/91e36dfa-44e3-4905-a186-3a988bd67ab8/small/dentsply-sirona-grey-80-black-rgb-jpg.JPG https://www.arubahealthmonitor.com/article/910342356-new-publication-demonstrates-tlx250-px-zircaix-potential-in-diagnosing-kidney-cancers-beyond-ccrcc Aruba Health Monitor en PressRelease 2026-05-04T21:00:00+00:00 New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://www.arubahealthmonitor.com/article/910333422-tango-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Aruba Health Monitor en PressRelease 2026-05-04T20:31:00+00:00 Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/d6e37a27-2e33-43bb-ae05-bfb0dedbf190/small/tango-logo-png.png https://www.arubahealthmonitor.com/article/910333352-teva-to-present-at-the-bofa-securities-health-care-conference Aruba Health Monitor en PressRelease 2026-05-04T20:30:00+00:00 Teva to Present at the BofA Securities Health Care Conference https://ml-eu.globenewswire.com/media/c2001734-949b-4cc2-8021-b4b64eda1f13/small/teva-rgb-jpeg-jpg.jpg https://www.arubahealthmonitor.com/article/910333368-vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Aruba Health Monitor en PressRelease 2026-05-04T20:30:00+00:00 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/dde67700-b1b4-40c4-b930-13bd71804762/small/vor-wordmark-rgb-fullcolor-070920-png.png https://www.arubahealthmonitor.com/article/910333377-cellectis-to-report-first-quarter-financial-results-on-may-11-2026 Aruba Health Monitor en PressRelease 2026-05-04T20:30:00+00:00 Cellectis to Report First Quarter Financial Results on May 11, 2026 https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png https://www.arubahealthmonitor.com/article/910333384-cellectis-publiera-ses-r-sultats-financiers-du-premier-trimestre-le-11-mai-2026 Aruba Health Monitor en PressRelease 2026-05-04T20:30:00+00:00 Cellectis publiera ses résultats financiers du premier trimestre le 11 mai 2026 https://ml.globenewswire.com/media/a84ce25b-a774-4635-9b79-d45241f5decc/small/cellectis-logo-png.png https://www.arubahealthmonitor.com/article/910333394-olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Aruba Health Monitor en PressRelease 2026-05-04T20:30:00+00:00 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/9c736753-c905-4bd1-ac3a-1444bea84331/small/olema-logo-rgb-png.png https://www.arubahealthmonitor.com/article/910333396-crispr-therapeutics-provides-business-update-and-reports-first-quarter-2026-financial-results Aruba Health Monitor en PressRelease 2026-05-04T20:30:00+00:00 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/5dac7d0d-131d-4047-bab7-db8e0719bf58/small/crispr-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910333417-jushi-holdings-inc-to-report-first-quarter-2026-financial-results-on-may-12-2026 Aruba Health Monitor en PressRelease 2026-05-04T20:30:00+00:00 Jushi Holdings Inc. to Report First Quarter 2026 Financial Results on May 12, 2026 https://ml.globenewswire.com/media/e65f15fd-322c-4847-83c5-ceafe27f97d5/small/jushi-png.png https://www.arubahealthmonitor.com/article/910333429-opus-genetics-announces-fda-acceptance-of-opgx-lca5-into-rare-disease-evidence-principles-rdep-program Aruba Health Monitor en PressRelease 2026-05-04T20:30:00+00:00 Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program https://ml.globenewswire.com/media/468baef1-3b2d-4353-a17e-cb41b45ee6ef/small/opus-rgb-r-jpg.jpg https://www.arubahealthmonitor.com/article/910333432-eton-pharmaceuticals-to-report-first-quarter-2026-financial-results-on-thursday-may-14-2026 Aruba Health Monitor en PressRelease 2026-05-04T20:30:00+00:00 Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 https://ml.globenewswire.com/media/db07cafa-b35c-4d61-a1a1-d330caf67ad2/small/eton-logo-png.png https://www.arubahealthmonitor.com/article/910333456-bioage-to-host-r-d-day-focused-on-nlrp3-inhibition-on-may-8-2026 Aruba Health Monitor en PressRelease 2026-05-04T20:30:00+00:00 BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 https://ml.globenewswire.com/media/d6df9eb5-87f7-4e2e-b503-8a7d8651428e/small/bioage-dark-logo-white-bg-500x500-png.png https://www.arubahealthmonitor.com/article/910333491-cvrx-announces-first-patient-enrollment-in-benefit-hf-a-landmark-heart-failure-trial-evaluating-barostim-in-significantly-expanded-population Aruba Health Monitor en PressRelease 2026-05-04T20:30:00+00:00 CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population https://ml.globenewswire.com/media/04c4feba-7841-4ac8-8ca5-6c03be383a0e/small/cvrx-outsmart-the-heart-logo-rgb-blue-png.png https://www.arubahealthmonitor.com/article/910333578-regional-health-properties-announces-appointment-of-marlie-davis-as-chief-financial-officer Aruba Health Monitor en PressRelease 2026-05-04T20:30:00+00:00 REGIONAL HEALTH PROPERTIES ANNOUNCES APPOINTMENT OF MARLIE DAVIS AS CHIEF FINANCIAL OFFICER https://ml.globenewswire.com/media/bfd51062-4a60-4cf0-9f2f-a4b109b52e4a/small/logo-jpg.jpg https://www.arubahealthmonitor.com/article/910333399-anaptys-to-participate-at-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference Aruba Health Monitor en PressRelease 2026-05-04T20:15:00+00:00 Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference https://ml.globenewswire.com/media/eb223f66-e7e0-4e0a-94e7-a3f7a06b13ab/small/anaptys-logo-png.png https://www.arubahealthmonitor.com/article/910333460-coopercompanies-appoints-paul-keel-to-its-board-of-directors Aruba Health Monitor en PressRelease 2026-05-04T20:15:00+00:00 CooperCompanies Appoints Paul Keel to its Board of Directors https://ml.globenewswire.com/media/10a4810f-301c-4d8c-851d-dd09334d10d5/small/coopercompanies-aqua-logo-horz-jpg.jpg https://www.arubahealthmonitor.com/article/910324477-inspiremd-reports-first-quarter-2026-financial-results Aruba Health Monitor en PressRelease 2026-05-04T20:05:00+00:00 InspireMD Reports First Quarter 2026 Financial Results https://ml-eu.globenewswire.com/media/5aefda10-5578-41c7-a1c0-9c4b700687c0/small/inspiremd-jpg.jpg https://www.arubahealthmonitor.com/article/910324487-option-care-health-to-participate-in-the-bank-of-america-health-care-conference Aruba Health Monitor en PressRelease 2026-05-04T20:05:00+00:00 Option Care Health to Participate in the Bank of America Health Care Conference https://ml.globenewswire.com/media/YWM2YTg3MzEtODAyYy00ZmVkLWE5YzUtNDk2YjA4MDU0ZWIxLTEwMTk5NzQtMjAyNi0wNS0wNC1lbg==/tiny/Option-Care-Health-Inc-.png https://www.arubahealthmonitor.com/article/910324540-kyntra-bio-to-report-first-quarter-2026-financial-results Aruba Health Monitor en PressRelease 2026-05-04T20:05:00+00:00 Kyntra Bio to Report First Quarter 2026 Financial Results https://ml.globenewswire.com/media/9105c1e9-d9e3-4b68-9fc8-261fed7db250/small/kyntra-bio-r-rgb-png.png https://www.arubahealthmonitor.com/article/910324650-capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12 Aruba Health Monitor en PressRelease 2026-05-04T20:05:00+00:00 Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 https://ml.globenewswire.com/media/16ce4387-5b8f-447c-96b8-7c453633f9bf/small/getimage-48-768x274-png.png https://www.arubahealthmonitor.com/article/910324654-lexicon-pharmaceuticals-announces-100-million-loan-facility-with-hercules-capital Aruba Health Monitor en PressRelease 2026-05-04T20:05:00+00:00 Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital https://ml.globenewswire.com/media/afcf3b59-ca71-40ed-9226-a0901bf4d13b/small/logo-jpg.jpg https://www.arubahealthmonitor.com/article/910324720-aktis-oncology-initiates-phase-1b-clinical-trial-for-aky-2519-a-b7-h3-miniprotein-radioconjugate-in-metastatic-castration-resistant-prostate-cancer Aruba Health Monitor en PressRelease 2026-05-04T20:05:00+00:00 Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) https://ml.globenewswire.com/media/490bbb9a-2b27-4a72-8d7a-333387326d8b/small/aktis-rgb-png.png https://www.arubahealthmonitor.com/article/910324723-akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Aruba Health Monitor en PressRelease 2026-05-04T20:05:00+00:00 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.arubahealthmonitor.com/article/910324766-oric-pharmaceuticals-reports-first-quarter-2026-financial-results-and-operational-updates Aruba Health Monitor en PressRelease 2026-05-04T20:05:00+00:00 ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates https://ml.globenewswire.com/media/acbc0ad2-7a44-4ee7-b729-ab92d57ffafb/small/oric-png.png https://www.arubahealthmonitor.com/article/910324634-inspire-medical-systems-inc-announces-first-quarter-2026-financial-results-and-updates-2026-guidance Aruba Health Monitor en PressRelease 2026-05-04T20:02:00+00:00 Inspire Medical Systems, Inc. Announces First Quarter 2026 Financial Results and Updates 2026 Guidance https://ml.globenewswire.com/media/194e83a5-3f7e-4805-88ce-da2e0ab594df/small/inspire-primary-logo-rgb-daylight-002-png.png https://www.arubahealthmonitor.com/article/910324758-ocugen-announces-private-offering-of-115-million-of-convertible-senior-notes Aruba Health Monitor en PressRelease 2026-05-04T20:01:51+00:00 Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png https://www.arubahealthmonitor.com/article/910324495-praxis-precision-medicines-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026-and-participate-in-upcoming-investor-conference Aruba Health Monitor en PressRelease 2026-05-04T20:01:00+00:00 Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://www.arubahealthmonitor.com/article/910324509-fibrobiologics-reports-preclinical-data-showing-fibroblast-spheroids-may-actively-reprogram-the-burn-wound-environment-to-drive-healing-and-reduce Aruba Health Monitor en PressRelease 2026-05-04T20:01:00+00:00 FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring https://ml.globenewswire.com/media/720fe0fe-52b4-4ccc-a5ad-95d4288f1df2/small/fibrobiologics-logo-2022-jpg.jpg https://www.arubahealthmonitor.com/article/910324510-biodesix-announces-first-quarter-2026-results-and-highlights Aruba Health Monitor en PressRelease 2026-05-04T20:01:00+00:00 Biodesix Announces First Quarter 2026 Results and Highlights https://ml.globenewswire.com/media/b2fd8e3c-ff04-47d9-938d-93c9c961ccc3/small/bdsx-logo-1200x240-png.png https://www.arubahealthmonitor.com/article/910324629-hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares Aruba Health Monitor en PressRelease 2026-05-04T20:01:00+00:00 Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares https://ml.globenewswire.com/media/M2UyM2ExNWYtYTJjYi00M2RhLTkwZGEtNjZlYTUyMzI4NTI4LTEzMjE4MjEtMjAyNi0wNS0wNC1lbg==/tiny/Hemab-Therapeutics-Inc-.png https://www.arubahealthmonitor.com/article/910324649-senseonics-announces-closing-of-92-million-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares Aruba Health Monitor en PressRelease 2026-05-04T20:01:00+00:00 Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares  https://ml.globenewswire.com/media/7f64f449-dd5d-4bd1-9504-82adb3846669/small/logo-png.png https://www.arubahealthmonitor.com/article/910324596-cytokinetics-to-announce-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive Aruba Health Monitor en PressRelease 2026-05-04T20:00:00+00:00 Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026 https://ml.globenewswire.com/media/52e2be9f-e9e3-43af-a747-123fdcac4253/small/cytokinetics-png.png https://www.arubahealthmonitor.com/article/910324676-providence-saint-john-s-health-center-reinforces-its-commitment-to-maternal-and-newborn-care-through-newly-named-maria-shriver-labor-delivery-and Aruba Health Monitor en PressRelease 2026-05-04T19:42:13+00:00 Providence Saint John’s Health Center Reinforces its Commitment to Maternal and Newborn Care Through Newly Named Maria Shriver Labor, Delivery and Family Wellness Unit https://ml.globenewswire.com/media/7f052405-cf27-4729-904d-589a86a37d33/medium/think-pink-for-women-s-wellness-supporting-providence-saint.jpg https://www.arubahealthmonitor.com/article/910306648-aegis-treatment-centers-launches-mobile-medication-vehicle-to-expand-access-to-addiction-care-in-pasadena-and-surrounding-areas Aruba Health Monitor en PressRelease 2026-05-04T18:45:00+00:00 Aegis Treatment Centers Launches Mobile Medication Vehicle to Expand Access to Addiction Care in Pasadena and Surrounding Areas https://ml.globenewswire.com/media/ZTNhY2M2NTAtZDZhMy00MDM4LWJmMjEtYzhiYzkwOGIwMDcyLTEyNzQyMTYtMjAyNi0wNS0wNC1lbg==/tiny/Pinnacle-Treatment-Centers.png https://www.arubahealthmonitor.com/article/910291496-sync-supplement-claims-evaluated-the-revive-daily-sunlight-loophole-formula-for-healthy-circadian-rhythm-support Aruba Health Monitor en PressRelease 2026-05-04T17:18:28+00:00 SYNC Supplement Claims Evaluated: The Revive Daily Sunlight Loophole Formula for Healthy Circadian-Rhythm Support https://zingfast.com/wp-content/uploads/2026/05/SYNC-Supplement.jpg https://www.arubahealthmonitor.com/article/910291435-sace-launches-out-in-the-open-campaign-for-sexual-violence-awareness-month Aruba Health Monitor en PressRelease 2026-05-04T17:10:11+00:00 SACE Launches “Out in the Open” Campaign for Sexual Violence Awareness Month https://ml.globenewswire.com/media/M2ZhZGI5YjgtZTI2NS00NmY1LTgzYTEtMmFhMTZmNzI3YmM3LTUwMDE2MjA1My0yMDI2LTA1LTA0LWVu/tiny/Sexual-Assault-Center-of-Edmon.png https://www.arubahealthmonitor.com/article/910291473-eascra-biotech-welcomes-dr-anne-yau-as-life-science-research-scientist Aruba Health Monitor en PressRelease 2026-05-04T17:04:04+00:00 Eascra Biotech Welcomes Dr. Anne Yau as Life Science Research Scientist https://ml.globenewswire.com/media/1eda41c1-8c5d-43f0-9198-b0a1570f47e6/medium/dr-anne-yau.jpg https://www.arubahealthmonitor.com/article/910278476-confluent-medical-technologies-announces-nitinol-wire-center-of-excellence Aruba Health Monitor en PressRelease 2026-05-04T16:00:00+00:00 Confluent Medical Technologies Announces Nitinol Wire Center of Excellence https://ml.globenewswire.com/media/028bf7c1-4bf6-4b3b-8629-3235829b9477/small/confluent-logo-color-png.png https://www.arubahealthmonitor.com/article/910272567-when-the-heart-can-t-keep-up-what-to-know-about-heart-failure Aruba Health Monitor en PressRelease 2026-05-04T15:28:08+00:00 When the Heart Can’t Keep Up: What to Know About Heart Failure https://ml.globenewswire.com/Resource/Download/79158b1b-2b4f-4818-8faa-7574106d7290/17877-1.jpg https://www.arubahealthmonitor.com/article/910272536-timelycare-acquires-alongside-to-expand-continuous-student-support-with-clinician-powered-ai-coaching Aruba Health Monitor en PressRelease 2026-05-04T15:00:00+00:00 TimelyCare Acquires Alongside to Expand Continuous Student Support with Clinician-Powered AI Coaching https://ml.globenewswire.com/media/51377623-fd82-411b-9c2c-22d85af45622/medium/alongside-by-timelycare.png https://www.arubahealthmonitor.com/article/910272574-awareness-is-key-3-steps-to-help-recognize-stroke-signs-and-risks-for-better-outcomes Aruba Health Monitor en PressRelease 2026-05-04T14:59:07+00:00 Awareness is Key: 3 Steps to Help Recognize Stroke Signs and Risks for Better Outcomes https://ml.globenewswire.com/Resource/Download/71a30026-5d47-467d-b6d5-c5bf1d2b31d8/17855-1.jpg https://www.arubahealthmonitor.com/article/910266581-flyte-increases-capacity-and-launches-hiring-initiative-as-spirit-airlines-shutdown-disrupts-u-s-air-travel Aruba Health Monitor en PressRelease 2026-05-04T14:30:00+00:00 Flyte Increases Capacity and Launches Hiring Initiative as Spirit Airlines Shutdown Disrupts U.S. Air Travel https://ml.globenewswire.com/media/cb9f10dc-be78-4c7c-a235-81bfdd77f03c/small/catheterlogo-jpg.jpg https://www.arubahealthmonitor.com/article/910266602-chopped-leaf-launches-new-premium-sandwich-lineup-featuring-toasted-ciabatta-creations Aruba Health Monitor en PressRelease 2026-05-04T14:24:08+00:00 Chopped Leaf Launches New Premium Sandwich Lineup Featuring Toasted Ciabatta Creations https://ml.globenewswire.com/media/ZGY0ZWI1OTEtNGNhNy00ZmFjLThhN2EtODM5YTdmNmVkMDUxLTEyNzIxMjEtMjAyNi0wNS0wNC1lbg==/tiny/The-Chopped-Leaf.png https://www.arubahealthmonitor.com/article/910262632-mmi-s-symani-surgical-system-treats-first-alzheimer-s-patient-in-groundbreaking-remind-study Aruba Health Monitor en PressRelease 2026-05-04T14:10:00+00:00 MMI’s Symani Surgical System Treats First Alzheimer’s Patient in Groundbreaking REMIND Study https://ml.globenewswire.com/media/e9325bed-8fcb-4abf-b66e-6f076014b0fb/small/mmi-logo-stacked-tagline-positive-rgb1-png.png https://www.arubahealthmonitor.com/article/910262611-research-on-new-class-of-treatments-for-ovarian-cancer-receives-725-000-in-funding-from-ovarian-cancer-canada-to-become-clinical-trial-ready Aruba Health Monitor en PressRelease 2026-05-04T14:00:00+00:00 Research on new class of treatments for ovarian cancer receives $725,000 in funding from Ovarian Cancer Canada to become “clinical trial-ready” https://ml.globenewswire.com/media/YWY2NGZiYWEtODcyZC00Y2I5LThkZGEtYmM5ZjlkYzFkNDMzLTEzMTI5NjUtMjAyNi0wNS0wNC1lbg==/tiny/Ovarian-Cancer-Canada.png https://www.arubahealthmonitor.com/article/910262626-spring-allergies-hit-lungs-hard-doctor-of-pharmacy-explains-what-actually-helps Aruba Health Monitor en PressRelease 2026-05-04T14:00:00+00:00 Spring Allergies Hit Lungs Hard: Doctor of Pharmacy Explains What Actually Helps https://ml.globenewswire.com/media/13a92186-d8d0-4494-9e0a-5fc1d2e363ee/small/betterbrand-logo-new-png.png https://www.arubahealthmonitor.com/article/910262571-xpress-wellness-acquires-wichita-s-mental-health-clinic-midwest-counseling-services Aruba Health Monitor en PressRelease 2026-05-04T13:57:00+00:00 Xpress Wellness Acquires Wichita’s Mental Health Clinic Midwest Counseling Services https://ml.globenewswire.com/media/3c8097b3-a387-4dd0-8063-4f48aad75699/small/xpress-wellness-logo-png.png https://www.arubahealthmonitor.com/article/910258243-cdc-host-tt-certification-for-siemens-healthineers-total-testosterone-test-expands-patient-access-to-gold-standard-equivalent-results Aruba Health Monitor en PressRelease 2026-05-04T13:30:00+00:00 CDC HoST-TT Certification for Siemens Healthineers Total Testosterone Test Expands Patient Access to Gold Standard Equivalent Results https://ml.globenewswire.com/media/c5f289d1-b23c-41d2-bfe1-0121523d54b6/small/ https://www.arubahealthmonitor.com/article/910258255-coherus-oncology-to-report-first-quarter-2026-financial-results-on-may-11-2026 Aruba Health Monitor en PressRelease 2026-05-04T13:30:00+00:00 Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026 https://ml.globenewswire.com/media/07437af0-8ae3-48cf-952b-18bc6b99ca7c/small/coherus-onc-logo-rgb-150-png.png https://www.arubahealthmonitor.com/article/910258286-alpha-tau-announces-100-local-disease-control-rate-and-favorable-safety-profile-observed-in-alpha-dart-pancreatic-cancer-trials-presented-at-ddw Aruba Health Monitor en PressRelease 2026-05-04T13:17:21+00:00 Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026 https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg https://www.arubahealthmonitor.com/article/910253033-greece-launches-world-s-first-national-wildfire-satellite-system-with-ororatech Aruba Health Monitor en PressRelease 2026-05-04T13:04:00+00:00 Greece Launches World’s First National Wildfire Satellite System with OroraTech https://ml.globenewswire.com/media/f405d4dd-2633-4e23-8086-bbaa6bf83b25/medium/ororatech-s-hellenic-fire-system.jpg https://www.arubahealthmonitor.com/article/910253114-aura-biosciences-announces-pricing-of-260-million-public-offering-of-common-stock-and-pre-funded-warrants Aruba Health Monitor en PressRelease 2026-05-04T13:03:06+00:00 Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://www.arubahealthmonitor.com/article/910252862-carnosyn-brands-expands-tribsyn-applications-across-beverage-dairy-and-medical-nutrition Aruba Health Monitor en PressRelease 2026-05-04T13:00:00+00:00 CarnoSyn® Brands Expands TriBsyn® Applications Across Beverage, Dairy, and Medical Nutrition https://ml.globenewswire.com/media/4b40dd5b-0137-41f8-83de-422e4b4f3196/small/nai-full-logo-green2-0-png.png https://www.arubahealthmonitor.com/article/910252869-oncolytics-biotech-reports-durable-responses-in-second-line-ras-mutant-mss-colorectal-cancer Aruba Health Monitor en PressRelease 2026-05-04T13:00:00+00:00 Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer https://ml.globenewswire.com/media/f0121259-b2be-4290-90a3-0d2c3b243aed/small/oncolytics-biotech-jpg.jpg https://www.arubahealthmonitor.com/article/910252878-curated-digital-health-works-now-there-s-a-claims-study-to-prove-it Aruba Health Monitor en PressRelease 2026-05-04T13:00:00+00:00 Curated Digital Health Works; Now There’s a Claims Study to Prove It https://ml.globenewswire.com/media/b8d88974-2aeb-4baa-ad3b-2ab758ed4dd9/small/solera-main-logo-red-png.png https://www.arubahealthmonitor.com/article/910252958-biomogging-brings-research-backed-rigour-to-looksmaxxing-as-the-discipline-goes-mainstream Aruba Health Monitor en PressRelease 2026-05-04T13:00:00+00:00 BioMogging Brings Research-Backed Rigour to Looksmaxxing as the Discipline Goes Mainstream https://ml.globenewswire.com/media/70c5dbfa-bae7-4e93-ac79-cd20cb471a59/medium/biomogging-brings-research-backed-rigour-to-looksmaxxing-as.png https://www.arubahealthmonitor.com/article/910252971-fate-therapeutics-announces-three-presentations-at-the-2026-asgct-annual-meeting-highlighting-off-the-shelf-car-t-cell-therapy-pipeline-for-cancer-and Aruba Health Monitor en PressRelease 2026-05-04T13:00:00+00:00 Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg